Search scope:
排序: Display mode:
Molecular classification and molecular targeted therapy of cancer
Miao Xu, Jianyong Shao, Yixin Zeng
Frontiers of Medicine 2013, Volume 7, Issue 2, Pages 147-149 doi: 10.1007/s11684-013-0274-2
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
Frontiers of Medicine 2009, Volume 3, Issue 3, Pages 245-255 doi: 10.1007/s11684-009-0044-3
Keywords: lung cancer carcinoma non-small cell lung cancer molecular markers targeted therapy
Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,
Frontiers of Medicine 2009, Volume 3, Issue 3, Pages 256-264 doi: 10.1007/s11684-009-0052-3
Keywords: target therapy gynecologic malignant tumors clinical trail molecular medicine
Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen
Frontiers of Medicine 2011, Volume 5, Issue 4, Pages 379-387 doi: 10.1007/s11684-011-0162-6
Keywords: nanoparticles superparamagnetic iron oxide targeted therapy molecular imaging cancer
Precision medicine in acute lymphoblastic leukemia
Ching-Hon Pui
Frontiers of Medicine 2020, Volume 14, Issue 6, Pages 689-700 doi: 10.1007/s11684-020-0759-8
Keywords: acute lymphoblastic leukemia molecular therapeutics targeted therapy tyrosine kinase inhibitors immunotherapy CAR T-cell therapy
Peter B. Alexander,Xiao-Fan Wang
Frontiers of Medicine 2015, Volume 9, Issue 2, Pages 134-138 doi: 10.1007/s11684-015-0396-9
Drug resistance is a major factor that limits the efficacy of targeted cancer therapies.mechanisms of resistance to receptor tyrosine kinase inhibitors, which are the most prevalent class of targeted
Keywords: targeted therapy drug resistance receptor tyrosine kinases cancer
Yue Yu, Jie He
Frontiers of Medicine 2013, Volume 7, Issue 2, Pages 157-171 doi: 10.1007/s11684-013-0272-4
Keywords: non-small-cell lung cancer molecular typing individualized medicine molecular-targeted therapy gene expression
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
Frontiers of Medicine 2021, Volume 15, Issue 2, Pages 221-231 doi: 10.1007/s11684-020-0812-7
Keywords: mTOR cancer therapy resistance GSK3 protein degradation E3 ubiquitin ligase PD-L1
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects
Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao
Frontiers of Medicine 2019, Volume 13, Issue 4, Pages 427-437 doi: 10.1007/s11684-018-0672-6
Keywords: targeted therapy desmoid-type fibromatosis tyrosine kinase inhibitor γ-secretase inhibitor
Progress and challenges in RET-targeted cancer therapy
Frontiers of Medicine 2023, Volume 17, Issue 2, Pages 207-219 doi: 10.1007/s11684-023-0985-y
Keywords: pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug
Frontiers of Medicine 2023, Volume 17, Issue 3, Pages 493-502 doi: 10.1007/s11684-022-0946-x
Keywords: situ hybridization immunohistochemistry variant allele frequency intratumoral heterogeneity targetedtherapy
Frontiers of Medicine 2023, Volume 17, Issue 2, Pages 275-289 doi: 10.1007/s11684-022-0945-y
Keywords: epidermal growth factor receptor ErbB receptors HM781-36B nasopharyngeal carcinoma molecular targetedtherapy cisplatin
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
Frontiers of Medicine 2021, Volume 15, Issue 1, Pages 1-10 doi: 10.1007/s11684-020-0741-5
Keywords: triple-negative breast cancer immunotherapy targeted therapy
Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells
XIONG Ying, GUO Wen, LI Ting, LI Ke
Frontiers of Medicine 2007, Volume 1, Issue 3, Pages 304-307 doi: 10.1007/s11684-007-0058-7
Keywords: control therapy influence Survivin-1 colorectal carcinoma
Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia Review
Meira Yisraeli Salman, Jacob M. Rowe, Nir Weigert
Engineering 2021, Volume 7, Issue 10, Pages 1354-1368 doi: 10.1016/j.eng.2021.05.020
Modern therapy of acute myeloid leukemia (AML) began in 1973 with the first report of the successfulof these advances have promoted the concept of personalized medicine, which has led to the advent of targetedSuch targeted agents have now become a cornerstone in the management of AML, increasing efficacy andThe focus of this review is on one of the most well-studied targeted agents in AML: the FMS-like tyrosinereview selectively discusses the FLT3 inhibitors in detail, as a model for the other burgeoning targeted
Keywords: AMLTargeted therapy FLT3 inhibitors Midostaurin Gilteritinib Quizartinib Sorafenib
Title Author Date Type Operation
Molecular classification and molecular targeted therapy of cancer
Miao Xu, Jianyong Shao, Yixin Zeng
Journal Article
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
Journal Article
Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory
Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,
Journal Article
Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging
Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen
Journal Article
Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
Peter B. Alexander,Xiao-Fan Wang
Journal Article
Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis
Yue Yu, Jie He
Journal Article
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
Journal Article
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects
Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao
Journal Article
Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy
Journal Article
A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma
Journal Article
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
Journal Article
Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells
XIONG Ying, GUO Wen, LI Ting, LI Ke
Journal Article